Cargando…

Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study

PURPOSE: The SAGIT® instrument, designed to assist clinicians to stage acromegaly, assess treatment response and adapt patient management, was well received by endocrinologists in a pilot study. We report an interim analysis of baseline data from the validation phase. METHODS: The SAGIT® validation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giustina, Andrea, Bronstein, Marcello D., Chanson, Philippe, Petersenn, Stephan, Casanueva, Felipe F., Sert, Caroline, Houchard, Aude, Melmed, Shlomo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728296/ https://www.ncbi.nlm.nih.gov/pubmed/31338660 http://dx.doi.org/10.1007/s11102-019-00977-5

Ejemplares similares

SAGIT(®): clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study
por: Giustina, Andrea, et al.
Publicado: (2015)

Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study
por: Petersenn, Stephan, et al.
Publicado: (2019)

A Consensus Statement on acromegaly therapeutic outcomes
por: Melmed, Shlomo, et al.
Publicado: (2018)

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study
por: Caron, Philippe J., et al.
Publicado: (2015)

A consensus on the diagnosis and treatment of acromegaly complications
por: Melmed, S., et al.
Publicado: (2012)

Use of Oral Concomitant Medications in Patients With Acromegaly
por: Petersenn, Stephan, et al.
Publicado: (2021)

Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis
por: Fleseriu, Maria, et al.
Publicado: (2023)

The potential utility of the SAGIT instrument in the clinical assessment of patients with acromegaly, a large single-centre study
por: Sawicka-Gutaj, Nadia, et al.
Publicado: (2023)

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
por: Giustina, Andrea, et al.
Publicado: (2012)

Molecular targets in acromegaly
por: Labadzhyan, Artak, et al.
Publicado: (2022)

THU061 Treatment Patterns In Acromegaly: Analysis Of Real-World US Insurance Claims From The MarketScan(®) Database
por: Fleseriu, Maria, et al.
Publicado: (2023)

Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study
por: Caron, Philippe, et al.
Publicado: (2018)

Correction to: Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study
por: Caron, Philippe, et al.
Publicado: (2018)

The sagital balance in idiopatic and neuromuscular scoliosis
por: Borges, Paulo Alvim, et al.
Publicado: (2014)

Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States
por: Fleseriu, Maria, et al.
Publicado: (2022)

Acromegaly
por: Chanson, Philippe, et al.
Publicado: (2008)

Darmstadt : De quoi s'agit-il?
Publicado: (1986)

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

Acromegaly in the elderly patient
por: Jallad, Raquel S., et al.
Publicado: (2019)

Erratum to: Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

STERNUM TOMOGRAPHIC EVALUATION IN PECTUS PATIENTS: ANALYSIS OF SAGITAL PARAMETERS
por: HAJE, DAVI DE PODESTÁ, et al.
Publicado: (2022)

Diagnosis of acromegaly: black, white… and sometimes gray!
por: Chanson, Philippe
Publicado: (2016)

A Pituitary Society update to acromegaly management guidelines
por: Fleseriu, Maria, et al.
Publicado: (2020)

Clinical, quality of life, and economic value of acromegaly disease control
por: Ben-Shlomo, A., et al.
Publicado: (2011)

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

Durable biochemical response and safety with oral octreotide capsules in acromegaly
por: Samson, Susan L, et al.
Publicado: (2022)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
por: Biller, Beverly MK, et al.
Publicado: (2010)

Multiple facets in the control of acromegaly
por: Vilar, Lucio, et al.
Publicado: (2013)

PMON66 A Systematic Literature Review to Evaluate Extended Dosing Intervals in the Pharmacological Management of Acromegaly
por: Fleseriu, Professor Maria, et al.
Publicado: (2022)

Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement
por: Casanueva, Felipe F., et al.
Publicado: (2017)

A practical approach to acromegaly management in Latin America
por: Bronstein, Marcello D., et al.
Publicado: (2013)

PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial
por: Elenkova, Atanaska, et al.
Publicado: (2022)

Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
por: Caron, Philippe J., et al.
Publicado: (2014)

Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
por: Carmichael, John D., et al.
Publicado: (2014)

LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly
por: Samson, Susan, et al.
Publicado: (2022)

La maladie de Weber-Christian: s'agit-il d'un état pré-leucémique?
por: Saghir, Salahiddine, et al.
Publicado: (2019)

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
por: Neggers, Sebastian JCMM, et al.
Publicado: (2015)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria
por: Rinke, Anja, et al.
Publicado: (2021)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cbh0fkdcfqrq80khkjlse2al7i